tbuckley/cabot-search huggingface dataset:
OP0033 Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity, but not Their Concentration, Are Associated with Increased Mortality in Patients with Rheumatoid Arthritis: Results from Two Large Independent Cohorts: Table 1
Authors: J. Humphreys, J. van Nies, J. Chipping, T. Marshall, A. van der Helm-van Mil, D. Symmons, S. Verstappen
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> In patients with inflammatory arthritis, the autoantibodies rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) have been associated with poor outcomes such as increased disease activity, radiographic progression and disability. However, the utility of antibody level in predicting prognosis of inflammatory arthritis, in particular rheumatoid arthritis (RA), has not clearly been established. <h3>Objectives</h3> To investigate RF and ACPA status and levels as predictors of mortality in two large cohorts of patients with early inflammatory arthritis (EIA). <h3>Methods</h3> Data from the Norfolk Arthritis Register (NOAR) and Leiden Early Arthritis Clinic (EAC) cohort were used. At baseline, patients had demographic data and smoking status recorded; RF, ACPA and inflammatory markers were measured in the local laboratories. Patients were flagged with national death registers until death or censor date. Antibody status was stratified as negative, low or high positive as defined in the 2010 criteria, firstly by either RF or ACPA level, secondly by RF level alone and thirdly by ACPA level alone. Finally, patients were grouped as seronegative, single antibody positive or double antibody (RF and ACPA) positive. Cox regression models were applied to explore associations between antibody status and mortality adjusting for age, sex, smoking status, inflammatory markers and year of enrolment. <h3>Results</h3> 4962 (NOAR: 3053, EAC: 1909) patients were included. 35% and 42% of patients were ACPA/RF positive in NOAR and EAC respectively. There were 787 deaths during 36 109 person years follow up in NOAR, and 275 deaths during 16 187 person years follow up in the EAC. When antibody status was stratified as negative, low or high positive, there were no consistent findings between the two cohorts. Double antibody positivity was associated with excess mortality in both cohorts compared to seronegative patients: NOAR and EAC respective adjusted HR (95% CI): 1.35 (1.06-1.71) and 1.58 (1.16-2.15). <h3>Conclusions</h3> Patients with EIA who are seropositive for both RF and ACPA have increased mortality compared to those who are single positive or seronegative. Antibody level in seropositive patients was not consistently associated with excess mortality. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4033
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Authors: James R. Berenson, Alan Lichtenstein, Lester Porter, Meletios A. Dimopoulos, Roldolfo Bordoni, Sebastian George, Allan Lipton, Alan Keller, Oscar Ballester, Michael J. Kovacs, Hilary A. Blacklock, Richard Bell, Joseph Simeone, Dirk J. Reitsma, Maika Heffernan, John Seaman, Robert D. Knight
Journal: New England Journal of Medicine (1996)

Skeletal complications are a major clinical manifestation of multiple myeloma. These complications are caused by soluble factors that stimulate osteoclasts to resorb bone. Bisphosphonates such as pamidronate inhibit osteoclastic activity and reduce bone resorption.Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy. The patients were stratified according to whether they were receiving first-line (stratum 1) or second-line (stratum 2) antimyeloma chemotherapy at entry into the study. Skeletal events (pathologic fracture, irradiation of or surgery on bone, and spinal cord compression), hypercalcemia (symptoms or a serum calcium concentration > or = 12 mg per deciliter [3.0 mmol per liter]), bone pain, analgesic-drug use, performance status, and quality of life were assessed monthly.Among 392 treated patients, the efficacy of treatment could be evaluated in 196 who received pamidronate and 181 who received placebo. The proportion of patients who had any skeletal events was significantly lower in the pamidronate group (24 percent) than in the placebo group (41 percent, P < 0.001), and the reduction was evident in both stratum 1 (P = 0.04) and stratum 2 (P = 0.004). The patients who received pamidronate had significant decreases in bone pain and no deterioration in performance status and quality of life. Pamidronate was tolerated well.Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma.
Aquagenic Wrinkling of Palms in Cystic Fibrosis
Authors: Lisa Weibel, Renate Spinas
Journal: New England Journal of Medicine (2012)

A 17-year-old girl presented with a 10-year history of transient excessive wrinkling of her palms after brief exposure to water and sweating. She reported some uncomfortable tightness of the skin during these epi¬sodes.
Added value of narrow band imaging and confocal laser endomicroscopy in detecting Barrett’s esophagus neoplasia
Authors: C. Jayasekera, A. Taylor, P. Desmond, F. Macrae, R. Williams
Journal: Endoscopy (2012)

<b>Background and study aims:</b> Advances in endoscopic imaging techniques have enabled more accurate identification of subtle mucosal abnormalities. The aim of the study was to assess the accuracy of predicting high grade dysplasia (HGD) and intramucosal cancer (IMC) in mucosa predicted as being nondysplastic vs. dysplastic by high definition white light endoscopy (HD-WLE), narrow band imaging (NBI), and confocal laser endomicroscopy (CLE). <b>Patients and methods:</b> A cross-sectional study was performed in a tertiary referral setting between February 2010 and September 2011. A total of 50 consecutive patients who were referred to St Vincent’s Hospital for management of dysplastic Barrett’s esophagus were included. A prediction of likely histology was made for each mucosal point (four-quadrant every 1 cm and any visible mucosal abnormality), first with HD-WLE, followed by NBI, and finally CLE. Biopsies were taken at all of these points. <b>Results:</b> A total of 1190 individual biopsy points were assessed. At histology, 39 biopsy points were found to harbor HGD and 52 biopsy points harbored IMC. For the detection of HGD/IMC the sensitivity, specificity, and accuracy were: HD – WLE, 79.1 %, 83.1 %, and 82.8 %; NBI, 89.0 %, 80.1 %, and 81.4 %; and CLE, 75.7 %, 80.0 %, and 79.9 %, respectively. All mucosal points with IMC and all patients with HGD were detected by targeted biopsies guided by HD-WLE and NBI without the need for random Seattle protocol biopsies. <b>Conclusions:</b> HD-WLE in combination with NBI is highly accurate in the detection of HGD/IMC. Performing targeted biopsies in the surveillance of Barrett’s esophagus is possible in expert centers.
AB1462-HPR Risk factors for visual loss in giant cell arteritis: a retrospective study of 374 patients
Authors: A. Zacharof, T. Margaritis, A. Kioumourtzis, G. Galanis, K. Kouninios
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To determine the risk factors—especially the effects of thrombocytosis—for permanent visual loss in patients with temporal arteritis. <h3>Methods</h3> Three hundred seventy-four patients with temporal arteritis (all biopsy proven) were retrospectively studied for the development of permanent visual loss. We used multivariate logistic regression analysis to determine which of 17 pretreatment characteristics were associated with visual loss. <h3>Results</h3> Visual ischemic manifestations occurred in 38 (10%) patients, including permanent visual loss in 13 (34%) patients. The independent predictors associated with an increased risk of permanent visual loss were a history of transient visual ischemic symptoms (odds ratio [OR] =6.3; 95% confidence interval [CI]: 1.4 to 29; P=0.02) and a higher platelet count (OR =3.7 per SD; 95% CI: 1.8 to 7.9; P=0.001). The presence of constitutional symptoms (OR =0.14; 95% CI: 0.02 to 0.77, P=0.01), polymyalgia rheumatica (OR =0.04; 95% CI: 0.01 to 0.48, P=0.02), and C-reactive protein level (OR =0.35 per SD; 95% CI: 0.13 to 0.92, P=0.03) were associated with a reduced risk. Upper limb artery involvement was excluded from the multivariate model, as no patients with that problem developed permanent visual loss. Of the 187 patients who presented with thrombocytosis (platelet count &gt;400×10<sup>9</sup>/L), 69 (37%) developed ischemic visual symptoms, compared with 34 (18%) of those without thrombocytosis. <h3>Conclusions</h3> An elevated platelet count is a risk factor for permanent visual loss in temporal arteritis. The finding of thrombocytosis in a patient with suspected temporal arteritis should emphasize the need for urgent treatment, with consideration of using inhibitors of platelet aggregation or anticoagulation therapy. <h3>Disclosure of Interest</h3> None Declared
Extracellular vesicle isolation and characterization: toward clinical application
Authors: Rong Xu, David W. Greening, Hong-Jian Zhu, Nobuhiro Takahashi, Richard J. Simpson
Journal: Journal of Clinical Investigation (2016)

Two broad categories of extracellular vesicles (EVs), exosomes and shed microvesicles (sMVs), which differ in size distribution as well as protein and RNA profiles, have been described. EVs are known to play key roles in cell-cell communication, acting proximally as well as systemically. This Review discusses the nature of EV subtypes, strategies for isolating EVs from both cell-culture media and body fluids, and procedures for quantifying EVs. We also discuss proteins selectively enriched in exosomes and sMVs that have the potential for use as markers to discriminate between EV subtypes, as well as various applications of EVs in clinical diagnosis.
P945 CLINICAL OUTCOME OF GASTRIC VARICES IN PATIENTS WITH PORTAL HYPERTENSION WITH OR WITHOUT CIRRHOSIS WITHOUT A PREVIOUS HISTORY OF BLEEDING
Authors: E. Ahn, P. Kortan, G. May, N. Marcon, G. Kandel, Y.I. Kim, S. Grover, M. Cirocco, F. Wong
Journal: Journal of Hepatology (2014)
Abstract LB-120: Oncogenic property of FOXP1 isoform3 in diffuse large B-cell lymphoma.
Authors: Saerom Kim, Soyeon Kim, Eunkyung Kim, Tae Min Kim, Dae Seog Heo
Journal: Cancer Research (2011)

Abstract Introduction. FOXP1 forkhead transcription factor is one of the markers of activated B-cell-like (ABC) subgroup of diffuse large B-cell lymphoma (DLBCL). High level expression of FOXP1 has been reported to have a poor prognosis and nine different truncated isoforms of N-terminally truncated FOXP1 were found apart from full length FOXP1. However, the biologic roles of isoforms are not fully investigated. In this study, oncogenic effect of FOXP1 smaller isoform3 (FOXP1.3) was evaluated and complementary regulation between FOXP1 and FOXP1.3 was investigated. Methods. Various B-cell lymphoma cell lines (BJAB, OCI-Ly-19, SU-DHL-6, U2932, U2940 and Daudi) were used to evaluate FOXP1 isoforms by immunoblotting and RT-PCR. Two different cell lines, U2932 (ABC-DLBCL) and U2940 (primary mediastinal B-cell lymphoma) cells were exposed to FOXP1-specific siRNA and transfected with FOXP1.3 plasmid tagged with flag for up to 48 hr, respectively. After silencing and over-expression of FOXP1, cell proliferation was measured by colorimetric technique. Therapeutic effects were also confirmed by the treatment of monoclonal anti-CD20 antibody, rituximab at a dose of 10 μg/106 cells for 3 days. Results. Differential patterns of expression of FOXP1 isoforms were detected in various DLBCL cell lines on both protein and mRNA levels. U2940 cells exhibited high level of endogenous FOXP1.3 compared with other cell lines. The suppression of FOXP1 by siRNA led to the over-expression of FOXP1.3 in DLBCL cell lines. Up-regulation of FOXP1.3 showed approx. 2.5 folds increase of cell proliferation by colorimetric assay. This was due to induction of survival pathways involving NF-κB and NFAT2 transcriptional factors, which are nuclear transcriptional factors that represent major neoplastic events in DLBCL. Activation of FOXP1.3 was also observed after exposure to rituximab. Rituximab suppressed FOXP1 and dramatically increased expression levels of FOXP1.3 simultaneously in a time-dependent manner. Conclusion. A novel oncogenic property of FOXP1.3 and its complementary regulation with FOXP1 in DLBCL cell lines was observed. These data also suggest a possible mechanism of resistance to rituximab treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-120. doi:10.1158/1538-7445.AM2011-LB-120
EFFECT OF BIVALIRUDIN VERSUS HEPARIN IN A CONTEMPORARY TAVR POPULATION OF WOMEN: RESULTS FROM THE BRAVO 3 RANDOMIZED TRIAL
Authors: Jaya Chandrasekhar, Anna Petronio, Thierry Lefevre, Christian Kupatt, Didier Tchetche, Nicolas Dumonteil, John Webb, Antonio Colombo, Stephan Windecker, David Hildick-Smith, Peter Boekstegers, Axel Linke, Eric Van Belle, Gennaro Sardella, Oliver Husser, Eberhard Grube, Efthymios Deliargyris, Promodoros Anthopoulos, Roxana Mehran, George Dangas
Journal: Journal of the American College of Cardiology (2016)
NCI Scientist 'Temping' in Top Genome Post
Authors: E. Blume
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article NCI Scientist ‘Temping’ in Top Genome Post Get access Elaine Blume Elaine Blume Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 9, 6 May 1992, Page 672, https://doi.org/10.1093/jnci/84.9.672 Published: 06 May 1992
A patient who changed my practice: I should have known better
Authors: C. Thomas
Journal: BMJ (2003)

When I was a second year medical student in Edinburgh I frequently had sore throats. I found them quite debilitating, and as I had not started my clinical studies I had little idea of the cause or what to do about them. I went to see the student health doctor on several occasions. He usually prescribed phenol gargle but occasionally “M&B.”

Eventually, either because of my frequent attendances or, more likely, to get me off his back, he said he would refer me to a specialist at Edinburgh Royal Infirmary. He started to write the referral letter, but the telephone rang and …
FRI0570-HPR Lumbar Repositioning is Influenced by Nonspecific Low Back Pain, Test Setup and Body Mass Index
Authors: C. Bauer, M. Ernst, F. Rast, S. Schelldorfer, A. Meichtry, J. Kool, J. Suni, M. Kankaanpää
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Low back pain (LBP) affects up to 84% of people in industrialized countries [1]. In 2005 the total direct costs of LBP in Switzerland amounted €2.6 billion [2]. Several studies have investigated deficits in proprioception in non specific LBP (NSLBP) patients by investigating lumbar spine position sense. These studies measured lumbar repositioning error (RE), with conflicting results regarding the association of LBP and RE [3-5]. Comparison between these studies is difficult as there are large differences in the measurement procedure. <h3>Objectives</h3> The aim of this study therfore was to analyse if RE is influenced by sub-acute nonspecific low back pain (NSLBP), the test setup and individual factors and to propose a good test setup. <h3>Methods</h3> We measured lumbar RE (absolute, constant, variable &amp; mean squared) with three test setups in a cross-sectional, laboratory study. 60 patients with NSLBP and 31 healthy participants were included. All participants were instructed to move from neutral position through half of their maximal lumbar range of motion and to reproduce the neutral position. We analysed Group, Test &amp; GroupXTest effects on RE and adjusted for individual factors such as body mass index (BMI), by fitting a linear mixed model for every main outcome measure. <h3>Results</h3> NSLBP patients produced a greater absolute (38% difference between groups), constant (60%) and mean squared error (70%) compared to controls. There was no group effect on variable error (8%). NSLBP patients were less accurate but not less consistent. The test setup influenced the magnitude and direction of RE. BMI influenced absolute and mean squared error. The magnitude and direction of RE depended on the test setup. <h3>Conclusions</h3> Tests for lumbar RE discriminate NSLBP patients from healthy participants but should be viewed with caution as their outcome depends on the test setup and BMI. We recommend two test setups and normalization for BMI for further use in clinical studies. <h3>References</h3> Walker BF. J Spinal Disord. 2000;13:205-17. Wieser S. et. al. Eur J Health Econ. 2011;12:455-67. Asell M. et. al. Arch Phys Med Rehabil. 257 2006;87:1170-6. Brumagne S. et.al. Spine. 267 2000;25:989-94. O9Sullivan K. et. al. Manual Therapy. 2013;18:526-32. <h3>Acknowledgements</h3> The Swiss Commission of Technical Innovation (CTI) funded this study. We thank Hocoma AG, (CH) for providing hardware and software. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5032
False-Negative Blood Pool Scan in Hepatic Angiosarcoma
Authors: N Katayama, Y Inoue, M Harada, T Ichikawa, K Shimoyamada, M Ikeda, T Itoh, Y Tsukune
Journal: Clinical Nuclear Medicine (1998)

Angiosarcoma is a rare form of primary hepatic neoplasm. Blood pool scans using Tc-99m red blood cells or Tc-99m human serum albumin (HSA) are known to be useful in the diagnosis of vascular tumors, including angiosarcoma. The authors report a large exophytic hepatic angiosarcoma in which Tc-99m HSA imaging failed to demonstrate increased radioactivity even on the 90-minute image.
PROGNOSIS AFTER A DIAGNOSIS OF CANCER IN CHRONIC HEART FAILURE PATIENTS: A LONG TERM FOLLOW-UP STUDY
Authors: Ann Bøcher Secher Banke, Morten Schou, Lars Videbaek, Jacob Møller, Finn Gustafsson, Jordi Dahl, Christian Torp-Pedersen, Lars Køber, Per Hildebrandt, Gunnar Gislason
Journal: Journal of the American College of Cardiology (2015)
Doctors should not change the way they prescribe for acne
Authors: W J Cunliffe
Journal: BMJ (1996)

Table 1-Estimated prenatal and postnatal prevalences (per 100 000) of diagnosis of Turner's syndrome karyotype by test method (amniocentesis or chorion villus sampling) and karyotype (45,X and others).Figures in parentheses are 95% confidence intervals Postnatal Prenatal prevalence among Karyotype prevalence untested girls Relative risk Amniocentesis without ultrasonography 45,X 64.6 (42.2 to 94.7) 16.0 (13.1 to 19.3) 4.0 (2.7 to 6.0) Others 84.5 (58.5 to 118.1) 15.6 (12.7 to 18.8) 5.4 (3.9 to 7.7) Total 149.1 (113.8 to 191.6) 31.5 (27.5 to 36.1) 4.7 (3.6 to 6.1) Chorion villus sampling without ultrasonography 45,X 271.2 (165.8 to 418.6) 16.0 (13.1 to 19.3) 17.0 (12.0 to 24.0) Others 40.7 (8.4 to 118.9) 15.6 (12.7 to 18.8) 2.6 (0.9 to 7.9) Total 311.9 (197.8 to 467.7) 31.5 (27.5 to 36.1) 9.9 (7.0 to 14.0)
Abstract P1-04-09: mTORC1 and Rictor expression in human breast cancer: correlations with clinicopathological parameters and disease outcome
Authors: U Wazir, A Kasem, AK Sharma, WG Jiang, K Mokbel
Journal: Cancer Research (2012)

Abstract BACKGROUND: mTOR (the mammalian target of rapamycin) plays a key role in regulation of cellular metabolism, growth, and proliferation. It forms two multi-protein complexes known as complex 1 (mTORC1) and 2 (mTORC2). Raptor and Rictor are the core proteins for mTORC1 and mTORC2 respectively. There is a growing body of evidence that mTORC1 is up-regulated in many cancers and plays a role in carcinogenesis. The aim of the study was to investigate the mRNA expression of mTOR and Rictor in human breast cancer and examine the relationship between their expression and clinicopathological parameters. METHODS: Specimens of breast cancer (BC) tissues (N = 150) and normal tissues (N = 31) underwent RNA extraction and reverse transcription. mTOR and Rictor transcript levels were determined using real-time quantitative PCR. Expression levels were analyzed against tumor size, grade, nodal involvement, TNM stage, and clinical outcome over a 10 year follow-up period. RESULTS: Significantly higher mRNA transcript levels of mTOR were found in the breast cancer specimens compared to normal glandular tissue (p = 0.0018). The expression of mTOR mRNA was demonstrated to increase with increasing NPI (53 for NPI1 to 219 for NPI3) and tumor grade (37 for grade 2 vs. 159 for grade 3, p = 0.047). mTOR expression was found to be higher in ductal tumors compared with non-ductal tumors (p = 0.0014). The patients who developed recurrent disease or died from breast cancer had higher expression levels than those who had been disease-free after a median follow-up period of 10 years (p = 0.17). Higher expression levels were significantly associated with worse overall survival (p = 0.01). In contrast, higher levels of Rictor mRNA expression were found in normal breast tissue, lower NPI stage (NPI1 vs. 2: p = 0.03) and lower tumor grade (grade 1 vs. grade 3: p = 0.01). Patients with higher Rictor expression had a significantly better overall (p = 0.037) and disease-free (p = 0.048) survival. CONCLUSIONS: mTOR expression was found to be significantly higher in BC specimens compared to normal breast tissue. Higher transcript levels were significantly associated with unfavorable pathological parameters and adverse clinical outcomes. The core protein of the less predominant mTORC2 was associated with favorable pathological parameters and clinical outcome. Taken together these observations are consistent with mTORC1 role in the anti-apoptosis pathway and suggest that selective inhibitors of mTORC1 are likely to be a more effective therapeutic strategy than dual inhibitors in human breast cancer. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-04-09.